{
    "symbol": "ASND",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-04 22:15:26",
    "content": "  Examples of such statements may include, but are not limited to our US commercialization and continued development of SKYTROFA for the US market, the commercialization of TransCon hGH for the EU market, our progress on our pipeline candidates, and our expectations, with respect to their continued progress, statements regarding the expected timing of approval and launch of TransCon PTH in the US market next year, statements regarding our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, statements regarding the US market approval of SKYTROFA, and our pipeline product candidates statements, regarding our planned regulatory filings, our expansion into new therapeutic areas, and statements regarding the ability to create a sustainable leading global biopharma company."
}